Literature DB >> 7293648

Pituitary apoplexy in acromegaly during bromocriptine therapy.

T Yamaji, M Ishibashi, K Kosaka, T Fukushima, T Hori, S Manaka, K Sano.   

Abstract

Two cases of pituitary apoplexy occurring in the course of long-term bromocriptine therapy for active acromegaly are described. Although bromocriptine was effective in lowering serum growth hormone levels and concomitant clinical improvement was achieved, both patients developed an acute episode suggesting pituitary apoplexy when the therapy was continued for 6 and 24 months, respectively. Surgery verified marked haemorrhage and necrosis of an eosinophilic pituitary adenoma in each case. Bromocriptine may have suppressed the growth of these pituitary adenomas resulting in necrosis of the tumour, followed by haemorrhage into the adenoma. Pituitary apoplexy has not been documented as a complication of bromocriptine therapy. This report points out a possible role of bromocriptine in the development of this catastrophe and that careful follow-up is required when long-term treatment with bromocriptine is attempted.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7293648     DOI: 10.1530/acta.0.0980171

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  11 in total

1.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 2.  Pituitary apoplexy.

Authors:  Wenya Linda Bi; Ian F Dunn; Edward R Laws
Journal:  Endocrine       Date:  2014-07-26       Impact factor: 3.633

3.  Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.

Authors:  Mirta Knoepfelmacher; Miriam C Gomes; Maria E Melo; Berenice B Mendonca
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

4.  Predictive Clinical and Surgical Factors Associated with Recurrent Apoplexy in Pituitary Adenomas.

Authors:  Alan Siu; Sanjeet Rangarajan; Michael Karsy; Christopher J Farrell; Gurston Nyquist; Marc Rosen; James J Evans
Journal:  J Neurol Surg B Skull Base       Date:  2021-09-10

5.  Pituitary macroadenomas: are combination antiplatelet and anticoagulant therapy contraindicated? A case report.

Authors:  Tricia Mm Tan; Carmela Caputo; Amrish Mehta; Emma Ci Hatfield; Niamh M Martin; Karim Meeran
Journal:  J Med Case Rep       Date:  2007-08-30

6.  Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

7.  Bromocriptine or cabergoline induced pituitary apoplexy: Rare but life-threatening catastrophe.

Authors:  Pratibha Singh; Manish Singh; Goutham Cugati; Ajai Kumar Singh
Journal:  J Hum Reprod Sci       Date:  2011-01

Review 8.  Recent developments in acromegaly: a review.

Authors:  A Jadresic
Journal:  J R Soc Med       Date:  1983-11       Impact factor: 18.000

Review 9.  Multidisciplinary Management of Pituitary Apoplexy.

Authors:  Adriana Albani; Francesco Ferraù; Filippo Flavio Angileri; Felice Esposito; Francesca Granata; Felicia Ferreri; Salvatore Cannavò
Journal:  Int J Endocrinol       Date:  2016-12-15       Impact factor: 3.257

10.  Pituitary apoplexy: an update on clinical and imaging features.

Authors:  Alessandro Boellis; Alberto di Napoli; Andrea Romano; Alessandro Bozzao
Journal:  Insights Imaging       Date:  2014-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.